Truist raised the firm’s price target on Elevance Health to $580 from $560 and keeps a Buy rating on the shares as part of a broader research note and outlook for FY24 among Healthcare Services names. Truist remains “broadly constructive” on core fundamentals across the group given “brisk sector tailwinds” around demand, the move to value-based care, and demographics, along with the group’s attractive positioning within segments and robust cash generation. The firm also notes that financial flexibility across much of the group should continue to underpin strong growth investment, M&A, and shareholder value creation, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ELV:
- Elevance, HCSC vying for Cigna’s Medicare Advantage unit, Bloomberg says
- Elevance, HCSC vying for Cigna Medicare Advantage unit, Bloomberg says
- Elevance Health price target lowered by $40 at BofA, here’s why
- Elevance Health price target lowered to $552 from $569 at JPMorgan
- Cigna price target raised to $351 from $345 at Deutsche Bank